Rapid Pathogen Screening (RPS) is taking back marketing rights specifically to eye care professionals in the U.S. and all medical professionals in Canada from Nicox to its AdenoPlus® adenoviral conjunctivitis (pink eye) test as well as two diagnostic tests. RPS is already in charge of marketing and manufacturing the AdenoPlus test to primary and urgent care professionals in the U.S. Per the restructured deal, Nicox will continue to commercialize AdenoPlus and the previously licensed development products in all markets outside North America.
RPS and Nicox signed a licensing agreement back in June of 2012 granting Nicox access to RPS’ point-of-care diagnostic tests for several different eye diseases and conditions, including pink eye. Nicox has reportedly paid a total of $3 million to RPS in license and option fees and has contributed to half of the costs of the two products in development. Per the new version of the agreement, Nicox will no longer contribute to development costs but may pay additional development milestones of up to $525,000 linked to approval of products outside North America.
Nicox can still purchase manufactured products from RPS at a discount and will pay single-digit royalties to RPS on sales of all products licensed outside North America. While Nicox can no longer market AdenoPlus and the development products in the U.S. or Canada, it still has a co-promotional option in these markets with therapeutics that complement these tests. RPS will pay Nicox single-digit royalties on sales of the relicensed products within the U.S. and Canada for the specific markets mentioned in the agreement.
RPS says that, going forward, marketing AdenoPlus and the development products to eye care professionals will be handled by its own eye care team, which the firm believes will speed up access for both existing and new customers. "Reacquiring the rights to AdenoPlus and future diagnostics in North America expands our eye care team’s product offerings, while maintaining a strong continued collaboration with Nicox outside North America," RPS' president and CEO Robert Sambursky, M.D., said in a statement.